secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107833
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics issues $182,400 convertible note to Vanquish Funding
--------------------------------------------------------------------------------

- Issued $182,400 promissory note (incl. $22,400 OID) to Vanquish Funding; net proceeds ~$155,000 after $5,000 fees.
- Note bears 12% interest (22% if unpaid), matures August 30, 2026; convertible at 35% discount to lowest 10-day trading price.
- Additional tranches up to $2M available over 12 months subject to further agreement with Vanquish.
- Conversion shares subject to 4.99% beneficial ownership cap; issued under Section 4(a)(2) exemption.
- Proceeds will be used for general working capital purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925107833/0001104659-25-107833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925107833/tm2530384d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer